Almac cracks £1bn milestone with global pharma growth

Almac Group has crossed the £1bn sales threshold for the first time, marking a standout year for the privately owned Craigavon-based pharmaceutical giant. With a 7% revenue rise and a 27% jump in pre-tax profits, the company is solidifying its position as a global partner of choice for drug manufacturing, distribution, and development.

Its reinvestment strategy is powering expansion across the US and Singapore, alongside a growing workforce of 7,700. With new licensing deals like its recent cancer treatment agreement in Taiwan, Almac is quietly redefining what long-term, independent growth looks like in a sector dominated by scale and speed.

For healthcare leaders watching the balance between specialisation, global reach, and sustainable growth—Almac’s playbook is worth a closer look.

Read the full article for insights on what’s driving Almac’s momentum